FDA Calendar

Company Name Repligen Corp
Drug Name SecreFlo (NDA)
Event Name FDA decision on SecreFlo for detection of pancreatic duct abnormalities
Event Date 06/21/2012
Outcome FDA issues complete response letter for SecreFlo (RG1068)
Drug Status
Rival Drugs
Market Potential
Other Approvals
Repligen Announces FDA Advisory Committee Date For SecreFlo NDA
Repligen - Eyeing Sustainable Profitability
Repligen Says FDA Cancels Advisory Committee Meeting
Repligen Obtains Complete Response Letter From FDA For RG1068 NDA
Return to FDA Calendar